89
Participants
Start Date
January 7, 2013
Primary Completion Date
May 12, 2015
Study Completion Date
May 12, 2015
Placebo
Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
WRSs2
WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
WRSs3
WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati
National Institute of Allergy and Infectious Diseases (NIAID)
NIH